Overview

* Acrivon Q3 net loss narrows to $18.2 mln from $22.4 mln last year

* Research and development expenses fell due to fewer milestones and focus on endometrial cancer

* Company has $134.4 mln in cash, funding operations into Q2 2027

Outlook

* Company expects cash to fund operations into Q2 2027

Result Drivers

* Research and development expenses were $13.6 million for the quarter ended September 30, 2025, compared to $18.9 million for the same period in 2024.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$18.23

Income mln

Q3 Basic -$0.47

EPS

Q3 -$19.69

Income mln

From

Operatio

ns

Q3 $19.69

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Acrivon Therapeutics Inc ( ACRV ) is $10.50, about 78.3% above its November 12 closing price of $2.28

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)